UPDATE - Cipher Pharmaceuticals announces NCIB to repurchase 10% of its public float, Launching paid tier.
NOV 15th, 2023 - Cipher Pharmaceuticals Announces Normal Course Issuer Bid
I’m currently in the process of assembling a body of research on an asset inside of Cipher Pharmaceuticals that has not been thoroughly covered anywhere on the web (in so far as I can tell). Management has also yet to provide much guidance relative to where they think sales might end up outside of a market size estimate. This is in contrast to the approximate guidance that’s been included inside the DCF analysis inside the latest Issuer Bid circular, which primarily modeled growth attributed to the marketing and sales of MOB-015. This will be paywalled for a subscription price of $8/month.
This Sunday I will also be publishing a body of research on a special situation which may appeal to some readers. In my view, there’s a potential for a ~20M USD company to earn well in excess of 500M USD after taxes before the end of 2030. This is obviously a fantastical claim, as nanocaps seldom go onto earn anything close to these sums. But I believe this is what circumstances and market positioning are pointing towards, and I look forward to sharing this research soon with those of you who chose to subscribe.
I will continue to post free content in the future.
Thank you for reading, and until next time.